-+ 0.00%
-+ 0.00%
-+ 0.00%

Akari Therapeutics wins Australian patent acceptance for Thailanstatin analog ADC payload

PUBT·04/27/2026 12:40:10
Listen to the news
Akari Therapeutics wins Australian patent acceptance for Thailanstatin analog ADC payload
  • Akari Therapeutics reported acceptance of an Australian patent application covering its PH1 RNA splicing modulator ADC payload technology.
  • Patent application 2024201765 includes composition-of-matter claims for second-generation Thailanstatin analogs intended for use in cancer-targeting ADCs.
  • Protection supports Akari ADC pipeline, including AKTX-101 and AKTX-102, which use the PH1 payload.
  • Akari expects AKTX-101 to enter Phase 1 first-in-human testing in late 2026 or early 2027 following IND-enabling studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.